No difference between semaglutide, placebo in fibrosis improvement in patients with NASH

Although semaglutide did not “significantly improve” fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, notable improvements were reported in cardiometabolic parameters and markers of liver fat and injury.“Previous studies in patients with NASH and stage 2 or 3 fibrosis have shown that semaglutide can improve NASH resolution over 72 weeks. However, there are limited data whether any therapy is effective in patients with NASH cirrhosis,” Rohit Loomba, MD, MHSc, director of hepatology and the NAFLD Research Center and vice chief ofRead More